Achieve Life Sciences, Inc.

ACHV • Biotechnology

$8.49

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$793.90M

Crecimiento

-100.0%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.69Liquidez saludable · 4.39Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 13 ago 2026, 12:11 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$8.49

Change0.00%

Shares Out93.51M

Market Cap$793.90M

Enterprise Value$621.55M

52W Range2.46 - 7.11

Beta2.23

P/E-6.96

P/B-54.10

P/FCF-16.88

EV/EBITDA-15.96

EV/FCF-13.21

Price$8.49

Change0.00%

Shares Out93.51M

Market Cap$793.90M

Enterprise Value$621.55M

52W Range2.46 - 7.11

Beta2.23

P/E-6.96

P/B-54.10

P/FCF-16.88

EV/EBITDA-15.96

EV/FCF-13.21

Earnings Yield-14.36%

FCF Yield-5.92%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.69

Current Ratio4.39

Quick Ratio4.39

Revenue 5Y-100.00%

Target$14.00

Target Upside64.90%

Target Median$13.00

Target Range12.00 - 18.00

Volume1.41M

Avg Volume1.72M

EPS Surprise0.11

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

72/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

20/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.69Liquidez saludable · 4.39Rentabilidad débil

Analyst view

Analyst sentiment and price target

ACHV

Analyst sentiment

Based on 6 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-13

Bajo

$12.00

Promedio

$14.00

Mediana

$13.00

Alto

$18.00

Resumen de la compañía

IPO: 10/12/1995

Industria: Biotechnology

P/B i: -54.10

Deuda / Patrimonio i: 0.69

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: 0.69

Ratio corriente: 4.39

Ratio rápido: 4.39

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Phelan Nancy R.

Transacción: 07/27/2026

COMPRA

Cambio

+16,700

Precio

Not reported

Presentación

07/29/2026

Tipo

COMPRA

Phelan Nancy R.

Transacción: 07/27/2026

COMPRA

Cambio

+25,000

Precio

$6.18

Presentación

07/29/2026

Tipo

COMPRA

Farrow Jeffrey S

Transacción: 07/27/2026

COMPRA

Cambio

+16,700

Precio

Not reported

Presentación

07/29/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Phelan Nancy R.	COMPRA	+16,700	Not reported	07/27/2026	07/29/2026
Phelan Nancy R.	COMPRA	+25,000	$6.18	07/27/2026	07/29/2026
Farrow Jeffrey S	COMPRA	+16,700	Not reported	07/27/2026	07/29/2026
Farrow Jeffrey S	COMPRA	+25,000	$6.18	07/27/2026	07/29/2026
Stewart Richard Alistair	COMPRA	+16,700	Not reported	07/27/2026	07/29/2026
Stewart Richard Alistair	COMPRA	+25,000	$6.18	07/27/2026	07/29/2026
Waldman Reid Alexander	COMPRA	+16,700	Not reported	07/27/2026	07/29/2026
Waldman Reid Alexander	COMPRA	+25,000	$6.18	07/27/2026	07/29/2026
Royston Aaron	COMPRA	+16,700	Not reported	07/27/2026	07/29/2026
Royston Aaron	COMPRA	+25,000	$6.18	07/27/2026	07/29/2026
Martin Christopher Nathan	COMPRA	+16,700	Not reported	07/27/2026	07/29/2026
Martin Christopher Nathan	COMPRA	+25,000	$6.18	07/27/2026	07/29/2026
Sellig Thomas	COMPRA	+16,700	Not reported	07/27/2026	07/29/2026
Sellig Thomas	COMPRA	+25,000	$6.18	07/27/2026	07/29/2026
Farrow Jeffrey S	OTRO	0	Not reported	05/29/2026	06/02/2026
Waldman Reid Alexander	OTRO	0	Not reported	05/29/2026	06/02/2026
Farrow Jeffrey S	COMPRA	+47,250	$5.24	05/29/2026	06/02/2026
Waldman Reid Alexander	COMPRA	+47,250	$5.24	05/29/2026	06/02/2026
Martin Christopher Nathan	OTRO	0	Not reported	05/11/2026	05/13/2026
Martin Christopher Nathan	COMPRA	+47,250	$5.59	05/11/2026	05/13/2026

Sobre la compañía

Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Fuente - Link

Competidores

ALLO ARCT AVIR CAPR HUMA IMRX SGMT TRDA VNDA VYGR

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve's board of directors approved stock option grants to purchase an aggregate of 315,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 283,000 shares of its common stock for 7 new employees under Achieve's 2024 Equity Inducement Plan.

GlobeNewsWire

Deutsche Bank AG Makes New $506,000 Investment in Achieve Life Sciences, Inc. $ACHV

Deutsche Bank AG purchased a new position in Achieve Life Sciences, Inc. (NASDAQ: ACHV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 77,485 shares of the biopharmaceutical company's stock, valued at approximately $506,000. Deutsche Bank AG

Defense World

Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new Chief Executive Officer, experienced commercial, CMC, and quality leaders, along with six new appointments to the Board of Directors Anticipates potential FDA approval in the first half of 2027, followed by U.S. commercial launch SEATTLE and VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced financial results for the second quarter of 2026 and provided business updates. “This quarter was about building Achieve to match the significant opportunity of cytisinicline,” said Andrew D.

GlobeNewsWire

Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality

SEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointments of Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain, and Gloria Cosgrove as Senior Vice President, Quality. Both executives bring decades of leadership across pharmaceutical manufacturing, supply chain, and quality.

GlobeNewsWire

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve's board of directors approved stock option grants to purchase an aggregate of 1,190,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 125,000 shares of its common stock for six new employees under Achieve's 2024 Equity Inducement Plan. The stock options have an exercise price equal to the closing price of Achieve's common stock on the grant date.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-12	-0.3	-0.19	0.11
2026-03-24	-0.27	-0.28	-0.01
2025-11-06	-0.24	-0.28	-0.04
2025-08-07	-0.37	-0.37	0
2025-05-13	-0.37	-0.37	0
2025-03-11	-0.3	-0.36	-0.06
2024-11-07	-0.26	-0.36	-0.1
2024-08-13	-0.22	-0.25	-0.03
2024-05-09	-0.24	-0.26	-0.02
2024-03-28	-0.32	-0.26	0.06
2023-11-09	-0.34	-0.34	0
2023-08-14	-0.41	-0.43	-0.02